Sangamo launches auction for ST — 503 pain program as Chapter 11 asset sales close with $163.55 million proceeds
Sangamo set a fourth-quarter 2026 deadline for an auction of its clinical-stage ST-503 chronic neuropathic pain program. Asset sales completed through a court-supervised Section 363 process generated USD 163.55 million in gross cash proceeds. PTC bought the Fabry disease program ST-920 for USD 111 million in cash, with